APA (7th ed.) Citation

S, D., B, B., L, N., M, W., A, B., A, W., . . . C, G. (2024). Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC heart failure, 11(5), 2759. https://doi.org/10.1002/ehf2.14815

Chicago Style (17th ed.) Citation

S, Dobner, et al. "Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy." ESC Heart Failure 11, no. 5 (2024): 2759. https://doi.org/10.1002/ehf2.14815.

MLA (9th ed.) Citation

S, Dobner, et al. "Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy." ESC Heart Failure, vol. 11, no. 5, 2024, p. 2759, https://doi.org/10.1002/ehf2.14815.